An overnight switch to ropinirole therapy in patients with Parkinson's disease

Journal of Neural Transmission

Volumn 106, Issue 9-10, 1999, Pages 925-929

  Canesi, M ^a   Antonini, A ^a   Mariani, C B ^a   Tesei, S ^a   Zecchinelli, A L ^a   Barichella, M ^a   Pezzoli, G ^a,b  

^a PARKINSON INSTITUTE   (Italy)

^b NONE   (Italy)

Author keywords

Bromocriptine; Parkinson's disease; Pergolide; Ropinirole

Indexed keywords

BROMOCRIPTINE; PERGOLIDE; ROPINIROLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOSE CALCULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; SIDE EFFECT; TREATMENT PLANNING;

ACTIVITIES OF DAILY LIVING; AGED; ANTIPARKINSON AGENTS; BROMOCRIPTINE; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PARKINSON DISEASE; PERGOLIDE; THERAPEUTIC EQUIVALENCY;

EID: 0032700713     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050212     Document Type: Article

References (13)

1. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O'Brien CF (1997) Ropinirole for the treatment of early Parkinson's disease. Neurology 49: 393-399
2. Factor SA, Sanchez-Ramos JR, Weiner WJ (1988) Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy. J Neurol Neurosurg Psychiatry 51: 529-533
3. Hely MA, Morris JGL, Reid WGJ, O'Sullivan DJ, Williamson PM, Rail D, Broe GA, Magried S (1994) The Sydney multicentre study of Parkinson's disease: a randomised, prospeetive five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 57: 903-910
4. Jimenez-Jimenez FJ, Lopez-Alvarez J, Sanchez-Chapado M, Montero E, Miquel J, Sierra A, Gutirrez F (1995) Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Clin Neuropharmacol 18: 277-279
5. Kunkler RB, Osborn DE, Abbott RJ (1998) Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson's disease. Br J Urol 82: 147
6. Le Witt PA, Gopinathan G, Ward CD, Sanes JN, Dambrosia JM, Durso R, Calne DB (1982) Lisuride versus bromocriptine treatment in Parkinson disease: a double-blind study. Neurology 32: 69-72
7. Le Witt PA, Ward CD, Larsen TA, Raphaelson MI, Newman RP, Foster N, Dambrosia JM, Calne DB (1983) Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 33: 1009-1014
8. Montastruc JL, Rascol O, Senard JM, Rascol A (1994) A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up. J Neurol Neurosurg Psychiatry 57: 1034-1038
9. Olanow CW, Jenner P, Brooks D (1998) Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 44 [Suppl 1]: S167-S174
10. Pezzoli G, Martignoni E, Pacchetti C, Angeleri VA, Lamberti P, Muratorio A, Bonuccelli U, De Mari M, Foschi N, Cossutta E, Nicoletti F, Giammona F, Canesi M, Scarlato G, Caraceni T, Moscarelli E (1994) Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 9: 431-436
11. Rinne UK (1987) Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 37: 826-828
12. Sanchez-Chapado M, Angulo Cuesta J, Guil Cid M, Jimenez FJ, Lopez Alvarez YJ ( 1995) Retroperitoncal fibrosis secondary to treatment with levodopa analogues for Parkinson disease. Arch Esp Urol 48: 979-983
13. Shannon KM, Bennett JP, Friedman JH for the Pramipexole Study Group (1997) Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 49: 724-728